BRISTOL-MYERS SQUIBB COMPANY Notional Amount of Nonderivative Instruments
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Notional Amount of Nonderivative Instruments of EUR 950.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Derivative Instrument Detail
us-gaap:NotionalAmountOfNonderivativeInstruments · last filed 2018-02-13
- BRISTOL-MYERS SQUIBB COMPANY notional amount of nonderivative instruments for fiscal 2017 was 950.00M EUR, a 0.00% change from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY notional amount of nonderivative instruments for fiscal 2016 was 950.00M EUR, a 0.00% change from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY notional amount of nonderivative instruments for fiscal 2015 was 950.00M EUR, a 75.60% increase from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY notional amount of nonderivative instruments for fiscal 2014 was 541.00M EUR, a 0.00% change from fiscal 2013.
EUR
| Period end | Notional Amount of Nonderivative Instruments 12 month |
|---|---|
| 2017-12-31 | 950.00M EUR 10-K · filed 2018-02-13 |
| 2016-12-31 | 950.00M EUR 10-K · filed 2017-02-21 |
| 2015-12-31 | 950.00M EUR 10-K · filed 2016-02-12 |
| 2014-12-31 | 541.00M EUR 10-K · filed 2015-02-13 |
| 2013-12-31 | 541.00M EUR 10-K · filed 2014-02-14 |
USD
| Period end | Notional Amount of Nonderivative Instruments 12 month |
|---|---|
| 2017-12-31 | $1.13B 10-K · filed 2018-02-13 |
| 2016-12-31 | $993.00M 10-K · filed 2017-02-21 |
| 2015-12-31 | $1.04B 10-K · filed 2016-02-12 |
| 2014-12-31 | $662.00M 10-K · filed 2015-02-13 |
| 2013-12-31 | $741.00M 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |